There is no doubt that PD-1/PD-L1 blockade is effective in bladder cancer, and improved biomarker-based selection of patients with the potential for maximum benefit will further improve management while minimizing toxicity and financial costs. The gene discussed is CD274; the disease is urinary bladder cancer.